Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

This study demonstrated that measurements of exhaled nitric oxide may provide a predictive tool for assessing response to treatment in COPD patients hospitalized with acute exacerbations. Background and objective: Fractional exhaled nitric oxide (FENO) has been implicated as a pulmonary biomarker in various respiratory diseases, including COPD. In this longitudinal study, the benefit of measuring FENO in a routine clinical setting was assessed in COPD patients hospitalized with an exacerbation of the disease. Methods: FENO, lung function and blood gases were measured in 58 COPD patients at hospital admission due to an exacerbation, and at discharge following treatment with corticosteroids and bronchodilators. Results: FENO levels were significantly decreased at discharge, compared with those at admission (geometric mean 25.3 ppb (95% CI: 21.2-30.1) vs 19.7 ppb (95% CI: 17.2-22.6); P = 0.002). There was a significant positive correlation between FENO concentrations at admission and the increase in FEV1 after treatment (r = 0.441, P <0.001), and a significant inverse correlation between FENO values at admission and the mean length of hospital stay (r = -0.297, P = 0.016). Using receiver operating characteristic curve analysis, the optimum cut point for FENO as a predictor for significant increase in FEV1 was 26.8 ppb (sensitivity: 74%, specificity: 75%). There were no correlations between FENO levels and absolute values for lung function variables at admission or discharge. Conclusions: These data suggest that FENO levels determined at hospital admission may predict the overall response to treatment in COPD patients with acute exacerbations.

Original languageEnglish
Pages (from-to)472-477
Number of pages6
JournalRespirology
Volume15
Issue number3
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Chronic Obstructive Pulmonary Disease
Nitric Oxide
Therapeutics
Lung
Length of Stay
Bronchodilator Agents
ROC Curve
Longitudinal Studies
Disease Progression
Adrenal Cortex Hormones
Biomarkers
Gases
Sensitivity and Specificity

Keywords

  • Chronic obstructive pulmonary disease
  • Exacerbation
  • Exhaled nitric oxide
  • Lung function
  • Smoking

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{75ef2284fc8940f5a78bd34ec8ab0fa7,
title = "Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations",
abstract = "This study demonstrated that measurements of exhaled nitric oxide may provide a predictive tool for assessing response to treatment in COPD patients hospitalized with acute exacerbations. Background and objective: Fractional exhaled nitric oxide (FENO) has been implicated as a pulmonary biomarker in various respiratory diseases, including COPD. In this longitudinal study, the benefit of measuring FENO in a routine clinical setting was assessed in COPD patients hospitalized with an exacerbation of the disease. Methods: FENO, lung function and blood gases were measured in 58 COPD patients at hospital admission due to an exacerbation, and at discharge following treatment with corticosteroids and bronchodilators. Results: FENO levels were significantly decreased at discharge, compared with those at admission (geometric mean 25.3 ppb (95{\%} CI: 21.2-30.1) vs 19.7 ppb (95{\%} CI: 17.2-22.6); P = 0.002). There was a significant positive correlation between FENO concentrations at admission and the increase in FEV1 after treatment (r = 0.441, P <0.001), and a significant inverse correlation between FENO values at admission and the mean length of hospital stay (r = -0.297, P = 0.016). Using receiver operating characteristic curve analysis, the optimum cut point for FENO as a predictor for significant increase in FEV1 was 26.8 ppb (sensitivity: 74{\%}, specificity: 75{\%}). There were no correlations between FENO levels and absolute values for lung function variables at admission or discharge. Conclusions: These data suggest that FENO levels determined at hospital admission may predict the overall response to treatment in COPD patients with acute exacerbations.",
keywords = "Chronic obstructive pulmonary disease, Exacerbation, Exhaled nitric oxide, Lung function, Smoking",
author = "B. Antus and I. Barta and I. Horv{\'a}th and E. Csisz{\'e}r",
year = "2010",
month = "4",
doi = "10.1111/j.1440-1843.2010.01711.x",
language = "English",
volume = "15",
pages = "472--477",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations

AU - Antus, B.

AU - Barta, I.

AU - Horváth, I.

AU - Csiszér, E.

PY - 2010/4

Y1 - 2010/4

N2 - This study demonstrated that measurements of exhaled nitric oxide may provide a predictive tool for assessing response to treatment in COPD patients hospitalized with acute exacerbations. Background and objective: Fractional exhaled nitric oxide (FENO) has been implicated as a pulmonary biomarker in various respiratory diseases, including COPD. In this longitudinal study, the benefit of measuring FENO in a routine clinical setting was assessed in COPD patients hospitalized with an exacerbation of the disease. Methods: FENO, lung function and blood gases were measured in 58 COPD patients at hospital admission due to an exacerbation, and at discharge following treatment with corticosteroids and bronchodilators. Results: FENO levels were significantly decreased at discharge, compared with those at admission (geometric mean 25.3 ppb (95% CI: 21.2-30.1) vs 19.7 ppb (95% CI: 17.2-22.6); P = 0.002). There was a significant positive correlation between FENO concentrations at admission and the increase in FEV1 after treatment (r = 0.441, P <0.001), and a significant inverse correlation between FENO values at admission and the mean length of hospital stay (r = -0.297, P = 0.016). Using receiver operating characteristic curve analysis, the optimum cut point for FENO as a predictor for significant increase in FEV1 was 26.8 ppb (sensitivity: 74%, specificity: 75%). There were no correlations between FENO levels and absolute values for lung function variables at admission or discharge. Conclusions: These data suggest that FENO levels determined at hospital admission may predict the overall response to treatment in COPD patients with acute exacerbations.

AB - This study demonstrated that measurements of exhaled nitric oxide may provide a predictive tool for assessing response to treatment in COPD patients hospitalized with acute exacerbations. Background and objective: Fractional exhaled nitric oxide (FENO) has been implicated as a pulmonary biomarker in various respiratory diseases, including COPD. In this longitudinal study, the benefit of measuring FENO in a routine clinical setting was assessed in COPD patients hospitalized with an exacerbation of the disease. Methods: FENO, lung function and blood gases were measured in 58 COPD patients at hospital admission due to an exacerbation, and at discharge following treatment with corticosteroids and bronchodilators. Results: FENO levels were significantly decreased at discharge, compared with those at admission (geometric mean 25.3 ppb (95% CI: 21.2-30.1) vs 19.7 ppb (95% CI: 17.2-22.6); P = 0.002). There was a significant positive correlation between FENO concentrations at admission and the increase in FEV1 after treatment (r = 0.441, P <0.001), and a significant inverse correlation between FENO values at admission and the mean length of hospital stay (r = -0.297, P = 0.016). Using receiver operating characteristic curve analysis, the optimum cut point for FENO as a predictor for significant increase in FEV1 was 26.8 ppb (sensitivity: 74%, specificity: 75%). There were no correlations between FENO levels and absolute values for lung function variables at admission or discharge. Conclusions: These data suggest that FENO levels determined at hospital admission may predict the overall response to treatment in COPD patients with acute exacerbations.

KW - Chronic obstructive pulmonary disease

KW - Exacerbation

KW - Exhaled nitric oxide

KW - Lung function

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=77950203510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950203510&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2010.01711.x

DO - 10.1111/j.1440-1843.2010.01711.x

M3 - Article

C2 - 20210889

AN - SCOPUS:77950203510

VL - 15

SP - 472

EP - 477

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 3

ER -